Real-life experiences in a single center: efficacy of pirfenidone in idiopathic pulmonary fibrosis and fibrotic idiopathic non-specific interstitial pneumonia patients

BACKGROUND: Pirfenidone is the first antifibrotic drug approved for the treatment of idiopathic pulmonary fibrosis (IPF) and it is used in the treatment of other interstitial pneumonias, such as unclassifiable interstitial lung disease (ILD) and connective tissue-related ILD. This study examined the...

Descripción completa

Detalles Bibliográficos
Autores principales: Feng, Haoshen, Zhao, Yabin, Li, Zhenhua, Kang, Jian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7580189/
https://www.ncbi.nlm.nih.gov/pubmed/33070705
http://dx.doi.org/10.1177/1753466620963015

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7580189/
https://www.ncbi.nlm.nih.gov/pubmed/33070705
http://dx.doi.org/10.1177/1753466620963015

Ejemplares similares